BSIM Therapeutics announces selection of candidate compound for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

15 November, 2021

Large press release3

BSIM Therapeutics is pleased to announce the selection of its first drug candidate, BSIM-3A05D, a compound designed to address hereditary and wild-type transthyretin amyloidosis with cardiomyopathy presentation (ATTR-CM). ATTR-CM is a progressive and potentially fatal disease characterized by deposition of transthyretin (TTR) amyloid in the heart’s myocardium, and leading to heart failure. BSIM-3A05D unmatched binding affinity to transthyretin and its optimal pharmacokinetic properties holds high potential for a safe and efficacious treatment of ATTR-CM, and opens up new possibilities for the treatment of a growing population diagnosed with TTR-mediated cardiac amyloidosis, both as monotherapy or in combination therapies.

For full information, download the Press Release below.


By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more